

Patient ID <b>SA00125346</b>	Patient Name <b>VALIDATIONRNV, NORMALIFG23</b>	Birth Date <b>1980-10-31</b>	Gender <b>F</b>	Age <b>39</b>
Order Number <b>SA00125346</b>	Client Order Number <b>SA00125346</b>	Ordering Physician <b>CLIENT,CLIENT</b>	Report Notes	
Account Information <b>C7028846 DLMP Rochester</b>		Collected <b>21 Jan 2020 00:00</b>		

**Intact Fibroblast Growth Factor 23**
**59 pg/mL**
**1 SDL**
**Reference Value**  
 ≤59

**ADDITIONAL INFORMATION**

Intact FGF23 concentrations should be interpreted in conjunction with serum phosphate (phosphorus) measurements. The reference interval is based on the mid-95th percentile of healthy normophosphatemic individuals. In patients with X-linked hypophosphatemia (XLH), intact FGF23 concentrations are usually elevated, however, in some situations intact FGF23 concentrations within the healthy normophosphatemic reference

interval may be observed. The use of an intact FGF23 concentration greater than 22 pg/mL has been proposed for identification of patients suspected of XLH. The testing method is an enzyme-linked immunosorbent assay (ELISA) manufactured by MedFrontier. Values obtained with different methods may be different and cannot be used interchangeably. If this test is being ordered as a tumor marker, results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

**Received: 21 Jan 2020 09:13**
**Reported: 21 Jan 2020 09:23**
**Laboratory Notes**

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**Performing Site Legend**

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55901	William G. Morice M.D. Ph.D	24D1040592